Key result
Age over 50 is linked to ~4-fold higher median NT-proBNP in patients without comorbidities.
Why the study?
NT-proBNP concentrations are influenced by multiple comorbidities beyond CHF, complicating interpretation of reference normal values.
What are the reference normal values for NT-proBNP in patients presenting with shortness of breath who have normal echocardiograms and no anemia or renal impairment?
Observational
What are the reference normal values for NT-proBNP in patients presenting with shortness of breath who have normal echocardiograms and no anemia or renal impairment?
In patients without major comorbidities like anemia or renal impairment, the reference range for normal NT-proBNP over 50 years of age remains steady at ~1000 pg/ml, suggesting age-related increases in previous studies were likely due to concurrent comorbidities.
Answers are grounded in this paper and cite their sources.
May warrant age- and RI-adjusted NT-proBNP thresholds for CHF evaluation; leaves open prospective validation of diagnostic accuracy.
The natriuretic peptides, B-type natriuretic peptide (BNP) and NT-proBNP that have emerged as tools for diagnosing congestive heart failure (CHF) are affected by age and renal insufficiency (RI). NTproBNP is used in rejecting CHF and as a marker of risk for patients with acute coronary syndromes. This observational study was undertaken to evaluate the reference value for interpreting NT-proBNP concentrations. The hypothesis is that increasing concentrations of NT-proBNP are associated with the effects of multiple co-morbidities, not merely CHF, resulting in altered volume status or myocardial filling pressures. NT-proBNP was measured in a population with normal trans-thoracic echocardiograms (TTE) and free of anemia or renal impairment. Study participants were seen in acute care for symptoms of shortness of breath suspicious for CHF requiring evaluation with cardiac NTproBNP assay. The median NT-proBNP for patients under 50 years is 60.5 pg/ml with an upper limit of 462 pg/ml, and for patients over 50 years the median was 272.8 pg/ml with an upper limit of 998.2 pg/ml. We suggest that NT-proBNP levels can be more accurately interpreted only after removal of the major co-morbidities that affect an increase in this peptide in serum. The PRIDE study guidelines should be applied until presence or absence of comorbidities is diagnosed. With no comorbidities, the reference range for normal over 50 years of age remains steady at ~1000 pg/ml. The effect shown in previous papers likely is due to increasing concurrent comorbidity with age.
No takes yet. Share an insight, caveat, or question.
Bernstein et al. (2011) conducted an observational in Shortness of breath suspicious for CHF. Age > 50 years vs. Age < 50 years was evaluated on Median NT-proBNP concentration (pg/ml). In patients without comorbidities, median NT-proBNP was 272.8 pg/ml for those over 50 years compared to 60.5 pg/ml for those under 50 years.
Synapse has enriched 10 related papers. Consider them for comparative context: